The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal ...
The researchers conducted a double-blind, randomized, placebo-controlled trial involving 2,655 adults in 30 countries around the world. The study participants were suffering from primary or recurrent ...
The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and ...
A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...
Please provide your email address to receive an email when new articles are posted on . Treatment-emergent adverse events occurred in 66.4% of patients who received Rebyota vs. 60.2% on placebo. Most ...
— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...
Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results